There were approximately 10 million cancer survivors in the United States in 2001 (approximately 3.5% of the general population), and 22% of these had a colorectal cancer (1) . Several epidemiological studies have shown that risk of primary cancers following colorectal cancer is substantially greater than the risk of first primary cancers for the general population (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) . Possible reasons for an increased risk of cancers following a first cancer could be the long-term effects of treatment for the first cancer and an overall greater predisposition to cancer due to patient characteristics (both genetic and environmental factors) and gene-environment and gene-gene interactions (7, (22) (23) (24) . Cancers following a first cancer may be identified earlier because of increased surveillance.
A major inherited cancer syndrome is Lynch syndrome, also known as hereditary nonpolyposis colorectal cancer (HNPCC) (25) , which is caused by germline mutations in one of the four DNA mismatch repair (MMR) genes MLH1, MSH2, MSH6, or PMS2 (26) . Mutation carriers are at a substantially increased risk of cancers of the colon, rectum, endometrium, stomach, ovary, ureter, renal pelvis, brain, small bowel, hepatobiliary tract, and pancreas (27, 28) . Several studies have quantified the risks of these cancers in Lynch syndrome (29) (30) (31) (32) (33) (34) ; however, there have been relatively few studies of the risks of primary cancers following colorectal cancer in Lynch syndrome patients (35) (36) (37) . Knowledge of the risks of cancers for MMR gene mutation carriers presenting with colorectal cancer has the potential to impact patient management and subsequent proposed surveillance. In this study, we have estimated risks of the primary extracolonic cancers following colorectal cancer for MMR gene mutation carriers.
function, ie, tumor microsatellite instability (MSI) and/or a lack of MMR protein expression (by immunohistochemistry). Screening for the same germline mutations was performed for the participant from each clinic-based family who developed colorectal cancer at the youngest age, regardless of MSI or MMR protein expression status. Mutation testing for the MLH1, MSH2, and MSH6 genes was performed by Sanger sequencing or denaturing high-performance liquid chromatography (dHPLC), followed by confirmatory DNA sequencing. Large duplication and deletion mutations including those involving EPCAM, which lead to MSH2 methylation, were detected by multiplex ligation-dependent probe amplification (MLPA) according to the manufacturer's instructions (MRC Holland, Amsterdam, the Netherlands) (38, 40, 41) . PMS2 mutation testing involved a modified protocol from Senter et al. (31) , in which exons 1-5, 9, and 11-15 were amplified in three long-range polymerase chain reactions (PCRs), followed by nested exon-specific PCR/sequencing, whereas the remaining exons (exons 6, 7, 8, and 10) were amplified and sequenced directly from genomic DNA. Large-scale deletions in PMS2 were detected using the P008-A1 MLPA kit (MRC Holland, Amsterdam, the Netherlands). The relatives of probands with a pathogenic mutation, who provided a blood sample, underwent testing for the specific mutation identified in the proband.
Definitions
A pathogenic mutation was defined as a variant that was predicted to result in a stop codon, a frameshift mutation, a large duplication or deletion, or a missense mutation in the coding region or splice site previously reported within the scientific literature and databases to be pathogenic. Primary extracolonic cancers following colorectal cancer were defined as cancers in organs other than the colon and rectum diagnosed at least 1 year after the age at diagnosis of first primary colorectal cancer. Colon cancer was defined as any diagnosis of cancer within the proximal colon (C18.0-C18.4), distal colon (C18.5-C18.7), or an unspecified site of the colon (C18.8, C18.9, and C26.0). Rectal cancer included cancers of the rectosigmoid junction (C19.9) and rectum (C20.9 and C21.8).
Statistical Analysis
Time at risk for each carrier commenced at the age at his or her first diagnosis of colorectal cancer and ended at the age at his or her diagnosis of primary extracolonic cancer following colorectal cancer, last-known age, or age at death, whichever occurred first. For endometrial cancer, we excluded female mutation carriers who had had a hysterectomy before diagnosis of colorectal cancer (n = 87), and we censored at the age at hysterectomy (n = 44).
The Kaplan-Meier failure function was used to estimate cumulative risk (penetrance) for subsequent primary cancers at 10 and 20 years following diagnosis of colorectal cancer for all carriers combined; cumulative risk was stratified by the MMR gene that was mutated.
We estimated the standardized incidence ratio (SIR) for each of the following cancers: stomach (C16); small intestine (C17); "hepatobiliary tract" including liver and intrahepatic bile duct (C22), gall bladder (C23), and other and unspecified parts of biliary tract (C24); pancreas (C25); "kidney etc." including kidney except renal pelvis (C64), renal pelvis (C65), ureter (C66), and other and unspecified urinary organs (C68); urinary bladder (C67); brain (C71); "bone" including bone and articular cartilage of limbs (C40) and bone and articular cartilage of other and unspecified sites (C41); hematopoietic tissue (C42); lung (C34); breast (C50); prostate (C61); "endometrium" including corpus uteri (C54) and uterus, part unspecified (C55); and ovary (C56). These cancer categories were specifically chosen as they matched the categories used by the Cancer Incidence in Five Continents volumes (42) (43) (44) (45) , which we used to estimate the SIR for each cancer.
First, we calculated the risk of primary cancers following colorectal cancer in carriers of MMR gene mutations compared with the risk of primary cancers for the general population. We calculated the SIR as the observed numbers of primary cancer diagnoses following colorectal cancer for the MMR gene mutation carriers divided by the expected numbers of cancer diagnoses. The expected numbers of cancer diagnoses were calculated by multiplying the age-, sex-, country-and calendar period-specific incidence for the general population with the corresponding follow-up time in the study cohort. Age-, sex-, country-and calendar year-specific cancer incidences for the general population were obtained from Cancer Incidence in Five Continents for the calendar periods 1983-1987 (42), 1988-1992 (43), 1993-1997 (44) , and 1998-2002 (45) . The SIRs were estimated and stratified by: 1) age at diagnosis of colorectal cancer (<50 or ≥50 years), 2) site of first primary colorectal cancer (colon or rectum), 3) the MMR gene that was mutated, 4) the sex of the carriers, and 5) patient ascertainment (population-based or clinic-based). We conducted sensitivity analyses by excluding carriers who had any cancer before or at the age at diagnosis of the primary colorectal cancer (n = 97). The 95% confidence intervals (CIs) of the cumulative risks and the SIRs were calculated using the 2.5th and 97.5th percentiles from 10 000 bootstrap samples, using the family as the resampling unit to allow for clustering within families.
Next, we calculated the risk of primary cancers following colorectal cancer for carriers of MMR gene mutations compared with the risk of primary cancers following colorectal cancer for the general population. This ratio was calculated by dividing the SIR by the risk of primary cancers following colorectal cancer for the general population, which was obtained from the New Malignancies Among Cancer Survivors: SEER Cancer Registries, 1973-2000 (17) . We calculated 95% CIs for this ratio based on observed and expected numbers of cancers using the method described by Breslow and Day (46) . All statistical analyses were performed using Stata 11.0 (47 The most common primary cancers following colorectal cancer in Lynch syndrome patients of both sexes were located in the urinary tract, with a total of 43 (5.6%) cancers including 13 in the kidney, two in the renal pelvis, seven in the ureter, two in both the renal pelvis and the ureter, one in the urethra, and 18 in the urinary bladder. During the 10 years following diagnosis with colorectal cancer, approximately 2% of carriers were diagnosed with cancer of the kidney, renal pelvis, ureter, or urethra (20-year risk = 5%), and approximately 2% were diagnosed with bladder cancer (20-year risk = 3%) ( Table 2) . Following colorectal cancer, carriers were at approximately 13-fold increased risk of cancers of the kidney, renal pelvis, ureter or urethra (SIR = 12.54, 95% CI = 7.97 to 17.94) and at approximately sevenfold increased risk of urinary bladder cancer (SIR = 7.22, 95% CI = 4.08 to 10.99) compared with the general population ( Table 3) . The other common primary cancers following colorectal cancer for Lynch syndrome patients were upper gastrointestinal cancers: there were 17 (2.2%) cancers in the small intestine (11 in the duodenum, two in the jejunum, and four were unspecified) and nine (1.2%) cancers in the stomach (one in the fundus and one in the greater curvature of the stomach; seven were unspecified). During the 10 years following colorectal cancer, the cumulative risk was approximately 1% for small intestinal cancer (20-year risk = 4%) and 0.7% for gastric cancer (20-year risk = 1%; Table 2 ). Following colorectal cancer, carriers had a more than 70-fold increased risk of small intestinal cancer (SIR = 72.68, 95% CI = 39.95 to 111.29) and a nearly sixfold increased risk of gastric cancer (SIR = 5.65, 95% CI = 2.32 to 9.69) compared with the general population (Table 3) .
We observed seven (9.2%) cancers in the hepatobiliary tract of Lynch syndrome patients who had had colorectal cancer (five in the liver, one in the gall bladder, and one in the unspecified part of biliary tract) and, following colorectal cancer, mutation carriers had a sixfold increased risk of hepatobiliary cancer (SIR = 5.94; 95% CI = 1.81 to 10.94) compared with the general population. We also observed five (0.7%) cancers in hematopoietic tissue (four in the bone marrow and one in the hematopoietic system, unspecified), five (0.7%) brain cancers (one in the cerebrum, one in the frontal lobe, and three in the brain, unspecified), two bone cancers (one in the scapula and long bones of upper limb, and one in the bone and articular cartilage, unspecified), four lung cancers, and three pancreatic cancers; however, these cancer risks were not statistically significantly greater than for the general population ( Table 3) .
The most common primary cancer following colorectal cancer for Lynch syndrome-carrying women was endometrial cancer, with a total of 45 (11.8%) patients and 40-fold increased risk compared with the general population (SIR = 40.23, 95% CI = 27.91 to 56.06). We also observed 20 (5.2%) breast cancers (SIR = 1.76, 95% CI = 1.07 to 2.59 for all carriers combined; Table 3) , driven primarily by cancers arising in MSH2 mutation carriers (SIR = 2.36, 95% CI = 1.19 to 3.73; Table 4 ). There were only six (1.6%) ovarian cancers (SIR = 4.19, 95% CI = 1.28 to 7.97 for all carriers combined; Table 3 ) but again mainly in the MSH2 group (SIR = 5.83, 95% CI = 1.29 to 12.71; Table 4 ). During the 10 years following colorectal cancer, the cumulative risk was approximately 12% for endometrial cancer (20-year risk = 24%), 2% for breast cancer (20-year risk = 11%), and 1% for ovarian cancer (20-year risk = 2%; Table 2 ). For Lynch syndrome-carrying men, we observed 19 (5%) prostate cancers, with a median age at diagnosis of 64 years (range: 55-77 years; Table 3 ), of which 15 arose in MSH2 mutation carriers (Table 4) . During the 10 years following colorectal cancer, about 3% of men were estimated to be diagnosed with prostate cancer (20-year risk = 6%; Table 2 ). Overall, we estimated a twofold increased risk of prostate cancer for all carriers combined, compared with the general population (SIR = 2.05, 95% CI = 1.23 to 3.01; Table 3 ), the vast majority of which were diagnosed for MSH2 mutation carriers (SIR = 3.62, 95% CI = 2.07 to 5.36; Table 4 ).
We observed no statistically significant differences in 10-and 20-year cumulative risks when stratified by the MMR gene that was mutated (data not shown). We observed no differences in the SIRs by the site of colorectal cancer (Table 5 ), the sex of the carriers (Supplementary Table 2 , available online), the age at diagnosis of colorectal cancer (Supplementary Table 3 , available online), and the method of case ascertainment (Supplementary Table 4 , available online). When we restricted the analysis to carriers without any cancer before or at age at first diagnosis of colorectal cancer, we still observed increased risks of primary cancers following colorectal cancer, except for hepatobiliary tract and breast cancers (Supplementary Table 5 , available online).
The increased site-specific risks that we observed were similar whether the reference incidences were for any primary cancer or only for cancer diagnosed subsequent to colorectal cancer. That is, the increased risk that we observed for cancer following colorectal cancer in MMR gene mutation carriers was substantially greater than the increased risk expected based on similar analysis in the general population (Table 5) .
Discussion
Some individuals with Lynch syndrome never develop a cancer, whereas most such individuals are diagnosed with one or more cancers during their lives, with colorectal cancer being the most common site. Previous research on cancer risks in Lynch syndrome patients has almost exclusively been about their risk of first cancers. The risk of cancers following a diagnosis of cancer in Lynch syndrome patients is not well understood. Two studies have estimated risks of colorectal cancer (35) or endometrial cancer (36) alone following colorectal cancer, and only one study has estimated risks for other types of cancers (37) . Addressing this knowledge gap may lead to more appropriate surveillance in colorectal cancer patients with Lynch syndrome. We have now estimated these risks using the largest study of Lynch syndrome colorectal cancer patients to date and we have observed that these patients have an increased risk of a greater range of cancers than the recognized spectrum of Lynch syndrome cancers, including breast and prostate cancers.
We derived most of our conclusions from analyses of all MMR gene mutation carriers combined because even with this large series of patients, there was insufficient power to fully distinguish some trends from random variation. Where feasible, we attempted to tease out the differences between the different MMR genes involved. We observed that the most common primary cancers following colorectal cancer, for both men and women who were Lynch syndrome carriers, were urinary tract cancers. Similar to our estimate of 5.2% risk of urinary tract cancers at 20 years following colorectal cancer, Aarnio et al. (37) * O = observed number of cancers; E = expected number of cancers; SIR = standardized incidence ratio of primary cancer following colorectal cancer for mismatch repair gene mutation carriers compared with risk of primary cancer for the general population; SIR 2 = standardized incidence ratio of primary cancers following colorectal cancer for mismatch repair gene mutation carriers compared with that for the general population. † Kidney etc. included kidney, renal pelvis, ureter, and other and unspecified urinary organs. ‡ Hepatobiliary tract included liver and intrahepatic bile duct, gall bladder, and other and unspecified parts of biliary tract. observed that colorectal cancer patients in the general population were at increased risk of renal pelvic cancer (SIR = 1.59, 95% CI = 1.31 to 1.91) and ureteral cancer (SIR = 2.00, 95% CI = 1.59 to 2.47). They further observed that the SIRs for these two cancers were greater 1) following colorectal cancer diagnosis at an early age than at a later age and 2) for those with multiple colorectal cancers, that is, those who were more likely to be MMR gene mutation carriers than those with single colorectal cancer. Although van der Post et al. (48) observed an increased risk of urinary tract cancers particularly for MSH2 mutation carriers, we observed increased risks for both MLH1 and MSH2 mutation carriers but had insufficient data to address MSH6 and PMS2 mutation carriers individually. There is no consensus that screening for urinary tract cancers should be considered for Lynch syndrome patients. Myrhøj et al. (49) observed that urine cytology is not a proper screening method for urinary tract cancer in Lynch syndrome patients. Current recommendations range from minimal surveillance ["consider annual urinalysis," per National Comprehensive Cancer Network version 1.2011 (50) ] to extensive surveillance ["a combination of ultrasonography of the bladder and upper urinary tract, urinary cytology, and urine sediment (erythrocytes) every 1-2 years starting at age 40" (48)].
Cancer of the small intestine is rare in the general population; however, it is one of the Lynch syndrome-spectrum tumors, with a lifetime risk in carriers of 4% (51-53) independent of development of colorectal cancer. Patients with Lynch syndrome-associated small intestinal cancers are diagnosed up to 20 years earlier than the median age for sporadic disease; also, in Lynch syndrome patients, the tumors are distributed along the small intestine in decreasing frequency from the duodenum to the ileum (54), whereas sporadic small intestinal cancer is largely a disorder of the duodenum (55) . In a case series of Lynch syndrome-associated small intestinal cancer, less than half represented the initial presentation of the disease, either alone or synchronously with another cancer, and there was no relationship found with gene, mutation type, sex, or personal or family history of cancer (56). In this study, risk of small intestinal cancer following colorectal cancer in Lynch syndrome patients was at more than 70 times the population risk, with the majority of instances occurring in the duodenum, with a median age of 55 years. The ability to visualize the remainder of the small intestine with computed tomography,ormagnetic resonance enterography, or video capsule endoscopy (54) has improved in recent years, but there is no current consensus on screening. Awareness of this risk, however, will encourage prompt investigation of unexplained iron deficiency or gastrointestinal symptoms that could relate to small bowel pathology.
Endometrial cancer was the most common cancer following colorectal cancer for women with Lynch syndrome, with statistically increased SIRs for carriers of mutations in MLH1 and MSH2. Using the same data source as our study, Obermair et al. (36) reported that Lynch syndrome-carrying women with colorectal cancer have a sixfold increased risk of endometrial cancer compared with women with microsatellite-stable colorectal cancer (hazard ratio = 6.24, 95% CI = 2.20 to 17.73). In the current study, we estimated Lynch syndrome patients' risk of endometrial cancer following colorectal cancer to be 40-fold greater than the endometrial cancer incidence in the general population. This apparent difference between the two studies may be explained by the use of different comparison groups (population incidence vs microsatellite-stable cases), different statistical methods (SIR vs Cox regression), and the incorporation of additional female MMR gene mutation carriers (n = 382 vs 112). Nevertheless, both studies confirm that women who have a previous diagnosis of colorectal cancer and carry MMR gene mutations are at very high risk of endometrial cancer. Similar to our 20-year-risk estimate of 24%, Aarnio et al. (37) observed that women with Lynch syndrome had a 20-year risk of approximately 27% for endometrial cancer following colorectal cancer although no confidence interval was reported. We also observed an increased risk of ovarian cancer following colorectal cancer in Lynch syndrome, with diagnoses made in MLH1 and MSH2 mutation carriers; however, only the MSH2 mutation carriers were at statistically significantly increased risk. According to the National Comprehensive Cancer Network guidelines (50), a prophylactic hysterectomy with bilateral salpingo-oophorectomy should be considered to reduce the risks of both endometrial and ovarian cancers in women with Lynch syndrome who have completed childbearing.
Overall, we observed a twofold increased risk of breast cancer in female carriers of Lynch syndrome mutations who been diagnosed with colorectal cancer; however, upon stratification by mutation type, this increase was only statistically significant for MSH2. The SIR for breast cancer was not statistically significant for MLH1 and MSH6 mutation carriers but because of the small number of patients and the wide CIs, we cannot state that heterogeneity of risk by gene exists. Because breast cancer is relatively common in the general population, demonstration of an increased risk requires larger numbers of subjects than has heretofore been available. The current study adds to the recent growing body of literature implicating MMR genes in some breast cancers (57) . In a prospective study of MMR gene mutation carriers from the Colon Cancer Family Registry, we have found a fourfold increased risk of breast cancer relative to the general population (58) . Also notable is that seven of the 20 women who developed breast cancer following colorectal cancer in this study have been previously reported to have lost MMR protein expression (59) , suggesting that the MMR defect caused by the mutation underlies the development of both colorectal and breast cancers in mutation carriers.
Increased incidence of prostate cancer has been previously reported in men with Lynch syndrome (60) and it is commensurate with that seen in BRCA2 mutation carriers (61, 62) . In this study, Lynch syndrome-carrying men were at a twofold increased risk for prostate cancer following colorectal cancer. However, when analysis was stratified for specific MMR gene mutations, only MSH2 mutation carriers had a statistically significantly increased risk, consistent with previous reports. Of eight prostate cancers in which MMR protein loss has been reported by previous studies (60, 63) , seven have involved MSH2 mutations and one has involved an MSH6 mutation. All immunohistochemistry results corresponded with the known underlying germline mutation.
The literature on Lynch syndrome through the years has included many case reports and series in which carriers of MMR gene mutations have developed cancers that are not widely considered to be part of the spectrum, including breast (64, 65) , prostate (66) , rhabdomyosarcoma (67), dermatofibrosarcoma (68), leiomyosarcoma (69), carcinoid syndrome (70) , and malignant fibrous histiocytoma (71) . In some of these patients, the tumor showed deficient DNA MMR. Following this logic, nearly any cancer that arises now and then in a mutation carrier might be labeled as being "part of the spectrum." In this study, we have documented evidence of increased risks of breast and prostate cancers in Lynch syndrome patients who have developed colorectal cancer due to MSH2 mutations (we cannot rule out a similar effect for the other genes). On the other hand, we have also noted no statistically significantly increased risk of some of the cancers traditionally linked with environmental influences, for example, lung cancer, consistent with the hypothesis that the initiating DNA lesions for those cancers are not regulated by MMR genes. The small number of observed lung cancers was probably not attributable to a nonsmoking cohort because, among a total of 764 carriers, 386 (53%) subjects were ever-smokers, 339 (47%) subjects were never-smokers, and the smoking status was not known for the remaining 39 subjects.
Does cancer risk change for a mutation carrier once they have been diagnosed with a colorectal cancer? The most studied cancer for MMR-mutation carriers, apart from colorectal cancer, is endometrial cancer. Hazard ratios of endometrial cancer for carriers who have not necessarily had a previous diagnosis of colorectal cancer, relative to the general population, were estimated to be 29.1 (95% CI = 16.5 to 51.1) for carriers of mutations in MLH1 and MSH2 combined (33), 25.5 (95% CI = 16.8 to 38.7) for MSH6 mutation carriers (29) , and 7.5 (95% CI = 2.8 to 20.0) for PMS2 mutation carriers (31) . Compared with these estimates, our estimate for endometrial cancer following colorectal cancer was not statistically different.
This study is, to our knowledge, the largest to date to investigate the risk of cancers at a wide range of sites following colorectal cancer in those with Lynch syndrome. All participating sites of the Colon Cancer Family Registry used standardized epidemiologic assessment and uniformly high-quality testing for MMR gene mutations. Attempts were made to verify primary cancers using pathology reports, medical records, corroboration by relatives, cancer registry reports, and/or death certificates, where available (38) .
There are some notable limitations of this study. We did not have data on histological type or specific types of some cancers in this analysis, for example, bone cancer and cancers of hematopoietic tissue. We used an arbitrary cutoff time point-at least 1 year after age at first diagnosis of colorectal cancer-to define a primary cancer following colorectal cancer. We were unable to account for treatment history that may have influenced the findings. Because patients with poor survival were less likely to be included in this analysis (they were unable to provide a blood sample for genetic testing and complete a questionnaire), there is a possibility that our results are not applicable to colorectal cancer patients with poor prognosis. Finally, because of the lack of comparative incidence data, we were unable to estimate site-specific SIRs separately for some of the other cancers, for example, those of the kidney, renal pelvis, ureter, and urethra, rather than all urinary tract cancers combined.
In summary, carriers of MMR gene mutations who have had a primary colorectal cancer are at increased risk of a range of cancers that includes cancers known to be associated with Lynch syndrome as well as breast and prostate cancers. These new data provide further determination of cancer risks, potentially informing and justifying ongoing studies to create the evidence for effective screening methodologies and intervals in MMR gene mutation carriers. Larger studies are needed to refine risk estimates separately for specific MMR gene mutations to best inform policies on clinical risk management.
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